[Bartter's syndrome].
D000042:Absorption; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001477:Bartter Syndrome / Q000175:diagnosis / Q000188:drug therapy / Q000503:physiopathology*; D001581:Benzothiadiazines; D003937:Diagnosis, Differential; D004232:Diuretics; D004359:Drug Therapy, Combination; D006801:Humans; D006929:Hyperaldosteronism / Q000503:physiopathology*; D007008:Hypokalemia / Q000209:etiology; D007610:Kallikreins / Q000502:physiology; D007684:Kidney Tubules / Q000503:physiopathology; D007705:Kinins / Q000502:physiology; D011189:Potassium Chloride / Q000008:administration & dosage; D011453:Prostaglandins / Q000502:physiology; D012084:Renin-Angiotensin System; D012965:Sodium Chloride / Q000378:metabolism; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage
D000893:Anti-Inflammatory Agents; D001581:Benzothiadiazines; D004232:Diuretics; D007705:Kinins; D011453:Prostaglandins; D049993:Sodium Chloride Symporter Inhibitors; D012965:Sodium Chloride; D011189:Potassium Chloride; D007610:Kallikreins
Das Bartter Syndrom.